Ranbaxy Laboratories has announced that its Malaysian joint venture Ranbaxy Malaysia Sdn Bhd has been allocated a site to set up a greenfield manufacturing facility. This will the drug major’s first greenfield facility in Malaysia and its second plant in that country.
Ranbaxy owns a 71 per cent stake in the venture. The facility, which will be spread across 15 acres, is likely to entail an investment of around $35 million and will provide employment to over 200 people, Ranbaxy said in a statement issued here.
It said the joint venture entity signed a signed a ‘letter of offer’ agreement with Kulim Hi Tech Park, a wholly-owned state agency and industrial park that houses various leading industries. The tech park is located at Kulim, in the State of Kedah, Malaysia.
The Government of Malaysia gave the Ranbaxy venture company an approval for setting up a greenfield manufacturing unit as an entry point project in September last year.
The new facility would manufacture tablets and capsules primarily in the cardiovascular, anti-diabetic, anti-infective and gastrointestinal segments. Once the plant becomes operational, Ranbaxy’s total output in Malaysia will go up from one billion doses a year to three billion doses each year.